Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Dense AC Followed by Paclitaxel with Trastuzumab in HER2+ Breast Cancer
NCT00591851Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2004
- Primary completion
- Jun 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in HER2-positive breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Cardiac Safety (Congestive Heart Failure Rate) at 18 months. Started Dec 2004; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00591851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00591851.